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Key Messages
￿ Although the FDA's recommended endpoint for IBS-C trials is useful for determining a medication's suitability
for regulatory approval, it may not provide adequate information to clinicians to guide appropriate patient-
speciﬁc treatment.
￿ The aim of this analysis was to evaluate the performance of the FDA IBS-C Responder Endpoint using data from
clinical trials of linaclotide.
￿ Pooled data from two Phase 3 IBS-C clinical trials of linaclotide were used to determine the percentages of FDA
endpoint non-responders reporting improvement in abdominal pain, bowel movement frequency, and/or global
relief measures.
￿ Clinically meaningful improvement in the key individual IBS-C symptoms of abdominal pain and stool
frequency was observed in >60% of linaclotide patients and >45% of placebo patients who did not meet the
FDA IBS-C Responder Endpoint.
Abstract
Background US Food and Drug Administration (FDA)
set a rigorous standard for deﬁning patient responders
in irritable bowel syndrome-C (IBS-C; i.e., FDA’s
Responder Endpoint) for regulatory approval. However,
this endpoint’s utility for health-care practitioners to
assess clinical response has not been determined. We
analyzed pooled IBS-C linaclotide trial data to evalu-
ate clinically signiﬁcant responses in linaclotide-
treated patients who did not meet the FDA responder
deﬁnition. Methods Percentages of FDA non-respond-
ers reporting improvement in abdominal pain, bowel
function and/or global relief measures were deter-
mined using pooled data from two linaclotide Phase 3
IBS-C trials. Key Results 1602 IBS-C patients enrolled;
34% of linaclotide-treated and 17% of placebo-treated
patients met the FDA Responder Endpoint
(p < 0.0001). Among FDA non-responders at week 12,
63% of linaclotide-treated patients reported their
abdominal pain was at least somewhat relieved,
compared with 48% of placebo-treated patients. For
stool frequency, 62% of linaclotide-treated patients
reported that they were at least somewhat improved at
week 12, compared with 46% of placebo-treated
patients. For global IBS symptoms, 65% of linaclo-
tide-treated patients reported at least some IBS-symp-
tom relief, 43% reported adequate relief of IBS
symptoms, and 57% reported being satisﬁed with
linaclotide treatment, vs placebo rates of 48%, 34%,
and 41% respectively. Conclusions & Inferences Most
linaclotide-treated IBS-C patients who were FDA non-
responders reported some improvement in abdominal
pain and stool frequency, and global relief/satisfac-
tion. In addition to the FDA Responder Endpoint,
differing response thresholds and symptom-speciﬁc
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Neurogastroenterology & Motilitychange from baseline should be considered by clini-
cians for a complete understanding of clinical response
to linaclotide and other IBS-C therapies.
Keywords abdominal pain, clinical response, com-
plete spontaneous bowel movement, guanylate
cyclase type-C receptor, IBS-C.
INTRODUCTION
Irritablebowelsyndrome(IBS),achronicgastrointestinal
disorder characterized by abdominal pain and/or dis-
comfort with altered bowel movements (BMs), is esti-
mated to affect up to 20% of the US adult population.
1
Irritable bowel syndrome negatively affects patients’
quality of life and is associated with a substantial
economic burden of care due to increased healthcare
resource utilization and diminished work productiv-
ity.
2–5InadditiontoabdominalpainandinfrequentBMs,
IBS with constipation (IBS-C) is characterized by clini-
cally relevant symptoms of abdominal bloating, hard
stools, straining, and a sensation of incomplete evacua-
tion.
6 Approximately one-third of patients with IBS
report symptoms consistent with IBS-C.
7
Linaclotide, a ﬁrst-in-class guanylate cyclase C
agonist, was recently approved by the US Food and
Drug Administration (FDA) and the European Medi-
cines Agency (EMA) for the treatment of IBS-C in adult
men and women. Linaclotide stimulates intracellular
production of cyclic guanosine monophosphate
(cGMP) by binding to guanylate cyclase C receptors
on the luminal surface of gastrointestinal epithelial
cells.
8 The increased cGMP results in chloride and
bicarbonate secretion into the gastrointestinal lumen,
and, consequently, increased ﬂuid secretion and accel-
erated intestinal transit.
9 Linaclotide has also been
shown to reduce visceral hypersensitivity in animal
models, which may be related to cGMP modulation of
afferent nerve activity in the extracellular space.
8,10,11
Two large Phase 3, multicenter, randomized, double-
blind, placebo-controlled, parallel-group, clinical trials
(Trials 31 and 302) documented the efﬁcacy of oral
linaclotide in patients with IBS-C.
12,13
The IBS-C responder endpoint recommended in the
May 2012 FDA ﬁnal guidance for industry on the
clinical evaluation of products for IBS (‘FDA Responder
Endpoint’) was assessed as a primary endpoint in both
trials.
14 The FDA Responder Endpoint requires
patients to have both an improvement of at least
30% in their daily worst abdominal pain and an
increase of 1 or more complete spontaneous bowel
movement (CSBMs) during the same week for at least
50% of the weeks of treatment. A CSBM is deﬁned as a
BM occurring in the absence of laxative, enema, or
suppository use during the previous 24 h, with the BM
accompanied by the patient self-reporting a feeling of
complete evacuation. This endpoint, designed with the
intent of better identifying a patient experiencing a
clinically meaningful improvement in IBS symptoms,
was shown to have high speciﬁcity and reasonable
sensitivity when it was evaluated using receiver-oper-
ator-characteristic-based methods.
15 However, because
this dichotomous endpoint reduces a patient’s level of
improvement/relief involving multiple IBS symptoms
to a single categorical responder/non-responder status,
the FDA Responder Endpoint results in an incomplete
clinical understanding of the effect of this treatment.
16
Therefore, the objective of these post-hoc analyses of
pooled data from both Phase 3 IBS-C linaclotide trials
was to evaluate clinical response in linaclotide-treated
patients who did not meet the FDA Responder End-
point (i.e., ‘FDA non-responders’) and to evaluate the
distribution of symptom improvement to allow better
understanding of clinical efﬁcacy.
MATERIALS AND METHODS
Clinical trial design
The two Phase 3 linaclotide clinical trials included a 2-week
baseline period, after which patients were randomized to receive
either placebo or linaclotide 290 lg once daily during a treatment
period of 12 weeks (Trial 31) or 26 weeks (Trial 302).
12,13
Study population
Patients were men and women aged 18 years or older who met
Rome II criteria for IBS.
6 Patients entering the baseline period were
required to report <3 spontaneous bowel movements (SBM = aB M
occurring in the absence of laxative, enema, or suppository use in
the previous 24 h, deﬁned in these trials as the calendar day of the
BM or the calendar day before the BM) per week and had 1 or more
of the following symptoms for at least 12 weeks, which need not
have been consecutive, in the preceding 12 months: (a) straining
during >25% of BMs, (b) lumpy or hard stools during >25% of BMs,
and (c) a sensation of incomplete evacuation during >25% of BMs.
During the baseline period, patients eligible for randomization
needed to report an average score of ≥3.0 for daily abdominal pain
at its worst on a 0–10 point numeric rating scale (NRS) and an
average of ≤5 SBMs per week and <3 CSBMs per week.
Efﬁcacy assessments and endpoints
Each day during the baseline and treatment periods, patients were
asked to call into an interactive voice response system (IVRS) to
record their IBS-C symptoms. Abdominal pain was measured
using an 11-point NRS; the number of BMs and use of rescue
medication were reported; and each BM was assessed for sensation
of complete bowel emptying (yes/no).
© 2013 Ironwood Pharmaceuticals.
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based on a patient’s average weekly response during week 12. For
abdominal pain, a patient’s weekly score, the average of the daily
IVRS responses across that week, was used to calculate percent
improvement from baseline. Similarly, the weekly rates of SBMs
and CSBMs during week 12 were used to calculate these change-
from-baseline endpoints.
As mentioned above, an FDA Endpoint Responder
14 was a
patient who met both of the following criteria in the same week for
at least six of the ﬁrst 12 weeks of the treatment period: (i) an
improvement of ≥30% from baseline in the average of the daily
worst abdominal pain scores and (ii) an increase of ≥1 CSBM from
baseline.Inaddition,patientswererequiredtocompleteatleastfour
IVRS calls during the week to qualify as a responder for that week.
In addition to daily rating of symptoms, patient rating of
change questions (PRCQs) for abdominal pain relief and SBM and
CSBM frequency improvement were asked at each study visit
following randomization, while an overall question, degree of
relief of IBS symptoms PRCQ, was asked weekly via the IVRS. For
abdominal pain relief, patients responded to the following PRCQ:
‘Compared to before you started this study, how would you rate
your abdominal pain at its worst during the past 7 days?’; for SBM
frequency improvement, patients responded to the following
PRCQ: ‘Compared to before you started this study, in the absence
of laxative use, how would you rate the frequency of your BMs
during the past 7 days?’; for CSBM frequency improvement,
patients responded to the following PRCQ: ‘Compared to before
you started this study, in the absence of laxative use, how would
you rate your frequency of complete BMs (i.e., BMs where you felt
like you completely emptied your bowels) during the past
7 days?’; and for degree of relief of IBS symptoms, patients
responded to the following PRCQ: ‘Compared to before you
started this study, how would you rate your IBS symptoms during
the past 7 days?’. For all four PRCQs, the response options were:
1 = Completely relieved/improved, 2 = Considerably relieved/
improved, 3 = Somewhat relieved/improved, 4 = Unchanged,
5 = Somewhat worse, 6 = Considerably worse, 7 = As bad as I
can imagine. A response of at least ‘somewhat improved’ has been
used as an anchor to determine minimal clinical signiﬁ-
cance.
15,17,18 ‘Somewhat improved’ represents the smallest differ-
ence in score in these PRCQ measures that patients perceive as
beneﬁcial, and that would mandate, in the absence of trouble-
some side-effects and excessive cost, a change in the patient’s
management.
19
Patients were also asked weekly if they had adequate relief of
their IBS symptoms with a yes/no response to the following
question: ‘Overall, have you had adequate relief from your IBS
symptoms during the past 7 days?’ Treatment satisfaction was
assessed at each postrandomization study visit by the following
question ‘Overall, how satisﬁed are you with the study medica-
tion’s ability to relieve your IBS symptoms?’ Patients selected
from the following 5-point ordinal response scale: 1 = Not at all
satisﬁed, 2 = A little satisﬁed, 3 = Moderately satisﬁed, 4 = Quite
satisﬁed, 5 = Very satisﬁed.
Safety assessments
At each scheduled study visit, all patients were asked an open-
ended question regarding adverse events (AEs). Patients reported
AEs by recalling instances since their prior visit. The site
investigator assessed all patient-reported AEs and judged each
event for severity and relationship to the blinded trial medication.
Other safety evaluations included physical examinations, electro-
cardiogram recordings, vital sign measurements, and standard
clinical laboratory tests.
Statistical methods and data analysis
The FDA Responder Endpoint was analyzed using a Cochran–
Mantel–Haenszel test, stratiﬁed by trial and geographic region,
comparing the linaclotide- and placebo-treatment groups. The
week 12 percent improvement from baseline for abdominal pain
and change from baseline for SBMs and CSBMs between the
linaclotide and placebo intent-to-treat (ITT) treatment groups were
compared using an analysis of covariance model with ﬁxed-effect
terms for treatment group, trial, and geographic region and the
corresponding baseline value as a covariate. In addition, the
percentageofpatientsineachtreatmentgroupwhometorexceeded
incrementally increasing threshold levels at week 12 was deter-
minedfor theabdominal andbowelsymptom endpoints.Ateachof
these thresholds, the percentage of linaclotide- and placebo-treated
patients meeting or exceeding this improvement threshold was
compared via a Fisher’s exact test.
To examine the effect of linaclotide on FDA non-responders,
the week 12 PRCQs, adequate relief, and treatment satisfaction
responder endpoints were summarized for three groups: linacl-
otide-treated patients who were FDA responders, linaclotide-
treated patients who were FDA non-responders, and placebo ITT
patients. If the linaclotide-treated patients who were FDA non-
responders were experiencing a clinical beneﬁt, the responder
rates should be higher than the placebo ITT patients. The
patient’s abdominal pain and bowel movement frequency PRCQ
endpoints were used to mitigate the potential bias of summa-
rizing endpoints using the same abdominal pain and bowel
movement frequency scores that deﬁne the stratiﬁcation (i.e.,
the FDA responder endpoint being used to stratify the results is
based on the abdominal pain and bowel movement frequency
scores). As the FDA non-responder patient population is based on
a postrandomization criterion to determine the population (i.e.,
whether a patient was an FDA responder based on the 12-week
treatment period), 95% conﬁdence intervals (CI) are presented
for the responder rates as opposed to a direct p-value based
comparison between the FDA non-responders and the placebo
ITT groups.
All p values were based on two-sided tests and all conﬁdence
intervals were two-sided. Efﬁcacy analyses were based on the
ITT Population (all patients in the Safety Population who had
at least one postbaseline efﬁcacy measurement for the primary
endpoint); safety analyses were based on the Safety Population
(all randomized patients who took at least one dose of study
drug).
RESULTS
Patient disposition, demographics, and baseline
characteristics
A total of 1605 IBS-C patients were included from both
Phase 3 IBS-C trials in the pooled Safety Population;
1602 of these patients were included in the ITT
Population. The demographics and baseline character-
istics of the ITT Population are shown in Table 1.
FDA responder endpoint
Across both Phase 3 trials, the FDA Responder End-
point was met by 271 (33.7%) of 805 linaclotide-treated
© 2013 Ironwood Pharmaceuticals.
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treated patients (a treatment difference of 16.2%, 95%
CI [12.0%, 20.4%] p < 0.0001). The clinical response of
linaclotide using PRCQs on abdominal pain and bowel
movement frequency in patients who were FDA non-
responders was investigated.
Clinical response in FDA non-responders
Using the PRCQs, greater than 90% of linaclotide-
treated patients who were FDA responders reported
their abdominal pain or stool frequency (SBM and
CSBM) being at least somewhat relieved or improved at
week 12 (Fig. 1). For linaclotide-treated patients who
were FDA non-responders, 63% (95% CI: 59%, 68%)
reported having at least ‘somewhat’ relief of abdominal
pain, while similar relief was reported by 48% (95% CI:
44%, 51%) of placebo-treated patients at week 12
(Fig. 1). Among linaclotide-treated FDA non-respond-
ers, 52% (95% CI: 47%, 56%) and 62% (95% CI: 58%,
66%) of patients reported having at least ‘somewhat’
improvement in the frequency of CSBMs and SBMs,
respectively, at week 12, compared with 39% (95% CI:
36%, 43%) and 46% (95% CI: 42%, 49%) of placebo-
treated patients (Fig. 1).
Similarly, among FDA non-responders a greater
percentage of linaclotide-treated patients reported
improvement in Degree of Relief, Adequate Relief,
and Treatment Satisfaction compared with placebo-
treated patients at week 12 (Fig. 2). Among linaclotide-
treated FDA non-responders at week 12, 65% (95% CI:
61%, 69%) reported at least ‘somewhat’ relief of their
Table 1 Summary of patient demographic and baseline characteristics (pooled phase 3 ITT population)
Linaclotide
290 lg( N = 805)
Linaclotide
290 lg FDA
responders (N = 271)
Linaclotide 290 lg FDA
non-responders (N = 534)
Placebo
(N = 797)
Demographic data
Age (years), Mean (range) 44.0 (19–82) 45.1 (21–78) 43.4 (19–82) 43.8 (18–87)
≥65 years, n (%) 42 (5.2) 16 (5.9) 26 (4.9) 43 (5.4)
Gender, n (%)
Female 735 (91.3) 257 (94.8) 478 (89.5) 708 (88.8)
Male 70 (8.7) 14 (5.2) 56 (10.5) 89 (11.2)
Race, n (%)
White 629 (78.1) 225 (83.0) 404 (75.7) 611 (76.7)
Black 148 (18.4) 40 (14.8) 108 (20.2) 153 (19.2)
Other 28 (3.5) 6 (2.2.) 22 (4.1) 33 (4.1)
BMI, Mean (SD) 28.0 (6.2) 28.1 (6.2) 28.0 (6.2) 27.7 (6.2)
Abdominal and bowel symptoms
Abdominal pain*, Mean (SD) 5.6 (1.7) 5.7 (1.7) 5.6 (1.7) 5.6 (1.7)
CSBMs/week, Mean (SD) 0.2 (0.4) 0.2 (0.5) 0.2 (0.4) 0.2 (0.5)
SBMs/week, Mean (SD) 1.8 (1.4) 2.0 (1.4) 1.8 (1.4) 1.8 (1.4)
*Assessed using an 11-point NRS: 0 = none; 10 = very severe.
BMI, body mass index; CSBM, complete spontaneous bowel movement; ITT, Intent-to-Treat; SBM, spontaneous bowel movement; SD, standard
deviation; NRS, numerical rating scale.
Figure 1 Percentage of patients reporting
improvement in abdominal pain, CSBMs,
and SBMs at week 12 for linaclotide FDA
responders/non-responders and placebo ITT
patients (pooled IBS-C phase 3 ITT
population; 95% CI). Patients on
linaclotide who were classiﬁed as FDA
responders and non-responders reported
higher rates of being somewhat,
considerably, or completely relieved/
improved compared to the placebo ITT
patients for abdominal pain, CSBMs, and
SBMs.
© 2013 Ironwood Pharmaceuticals.
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having adequate relief of their IBS symptoms, and 57%
(95% CI: 52%, 61%) reported being at least moderately
satisﬁed with linaclotide’s ability to relieve their IBS
symptoms, compared with 48% (95% CI: 44%, 52%),
34% (95% CI: 31%, 37%), and 41% (95% CI: 38%,
45%), respectively, of placebo-treated patients (Fig. 2).
Distribution of the efﬁcacy endpoints: linaclotide
vs placebo
Given that FDA non-responders show improvement in
PRCQs for abdominal pain, bowel movement fre-
quency, and global measures of IBS, the FDA Respon-
der Endpoint, as a dichotomous measure, fails to
capture the true breadth of clinical response. There-
fore, to more completely understand the clinical
beneﬁt of linaclotide, a wider distribution of percent
improvement in abdominal pain and stool frequency
(CSBM and SBM) was independently evaluated for the
linaclotide and placebo ITT Populations (Figs 3 and 4).
For all percent reductions (e.g., >10%, >20%, etc.) in
abdominal pain, more linaclotide-treated patients
reported improvement compared with placebo-treated
patients (Fig. 3). For example, 62% of linaclotide-
treated patients had an improvement in abdominal
pain at week 12 of at least 30% compared with 45% of
placebo-treated patients (p < 0.0001, Fig. 3). The mean
improvement in abdominal pain at week 12 in linacl-
otide-treated patients was 42% compared with 26% for
placebo-treated patients (p < 0.0001).
Similarly, the percentage of patients with speciﬁed
increases in weekly CSBM and SBM frequency at week
12 was greater for linaclotide-treated patients com-
pared with placebo-treated patients (Fig. 4). For exam-
ple, an increase of ≥1 CSBM per week from baseline
was reported by 46% of linaclotide-treated patients at
week 12 compared with 26% of placebo-treated
patients (p < 0.0001, Fig. 4). An increase of ≥2 SBMs
per week from baseline was reported by 59% of
linaclotide-treated patients at week 12 compared with
30% of placebo-treated patients (P < 0.0001, Fig. 4).
The mean increase in weekly CSBM frequency at week
12 among linaclotide-treated patients was 2.2 CSBMs/
week compared with an increase of 0.7 in placebo-
treated patients (p < 0.0001). The mean increase in
weekly SBM frequency at week 12 among linaclotide-
treated patients was 3.7 SBMs/week while the increase
was 1.0 in placebo-treated patients (p < 0.0001).
Safety results
A total of 440 of 807 linaclotide-treated patients (55%)
reported at least one AE over the ﬁrst 12 weeks of the
Figure 2 Percentage of patients reporting
improvement in degree of relief, adequate
relief, and treatment satisfaction at week 12
for linaclotide FDA responders/non-
responders and placebo ITT patients (pooled
IBS-C phase 3 ITT population; 95% CI).
Patients on linaclotide who were classiﬁed
as FDA responders and non-responders
reported higher rates of relief of IBS
symptoms compared with the Placebo ITT
patients for the following endpoints: degree
of relief of IBS symptoms (somewhat,
considerably, or completely relieved),
adequate relief of IBS symptoms, and
treatment satisfaction (moderately, quite, or
very satisﬁed with the treatment’s ability to
relieve IBS symptoms).
Figure 3 Percentages of patients with speciﬁed improvements in
abdominal pain at week 12 (pooled IBS-C phase 3 ITT population). At
week 12, a greater percentage of patients treated with linaclotide met
incremental levels of improvement in abdominal pain compared with
placebo patients (p < 0.0001 for linaclotide compared with placebo for
each percent level of improvement using Fisher’s exact test).
© 2013 Ironwood Pharmaceuticals.
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treated patients (50%). Most AEs were mild or moder-
ate in severity (94% linaclotide; 97% placebo). The
incidences of patients with diarrhea (19%), abdominal
pain (5%), and ﬂatulence (4%) AEs were greater in the
linaclotide group compared with the placebo group
(3%, 3%, and 2% respectively). Among these AEs only
diarrhea was reported more commonly in linaclotide
FDA responders (22%) compared with linaclotide FDA
non-responders (17%). None of the patients who
reported diarrhea experienced clinically signiﬁcant
sequelae (e.g., orthostatic hypotension or dehydration).
DISCUSSION
For IBS-C, the FDA’s guidance for the clinical evalu-
ation of drugs for IBS recommends a combined
responder endpoint requiring ≥30% improvement in
abdominal pain and an increase of at least 1 CSBM over
baseline, both in the same week, for at least 50% of the
treatment period. This FDA Responder Endpoint for
IBS-C clinical trials represents a rigorous and stringent
standard for the evaluation of IBS therapies for regula-
tory approval. As such, this combined endpoint should
be well-equipped to distinguish an efﬁcacious thera-
peutic agent from a placebo, which is critically impor-
tant in a ﬁeld where the placebo-response rate has
traditionally been quite high. However, the FDA
Responder Endpoint provides only a ‘snapshot’ of the
efﬁcacy of an investigational agent. By design, this
endpoint paints an incomplete picture of the therapeu-
tic beneﬁt of an agent such as linaclotide, as clinically
important individual symptom responses, such as
abdominal pain and stool frequency, among others,
are reduced to a single binary score. This methodologic
limitation is not unique to this particular IBS-C
responder endpoint but arises whenever continuous
response endpoints are dichotomized.
16 Although
designed to increase our ability to identify patient
‘responders’, the FDA Responder Endpoint does not
address patients who may have clinically important
and relevant responses but who do not meet the
stringent criteria of the endpoint. Given the chronic
non-life-threatening nature of IBS-C, a highly speciﬁc
and stringent endpoint may be desirable, even if
associated with a lower sensitivity, as it ensures there
is relative certainty that patients meeting the endpoint
have experienced a clinically meaningful beneﬁt.
However, it should be acknowledged that there are
patients who experience beneﬁt who do not meet the
FDA Responder Endpoint. As such, to appropriately
assess the ability of a medication to relieve symptoms,
it is important that patients’ symptom-speciﬁc
responses are considered in addition to dichotomous
responder endpoints. These assessments of individual
symptoms are particularly critical in the ﬁeld of IBS in
which symptom expression and symptom intensity
vary from patient to patient.
To illustrate this methodological limitation, we
evaluated symptom improvement in linaclotide-trea-
ted patients who were FDA non-responders. At week
12 linaclotide-treated FDA non-responders were eval-
Figure 4 Percentages of patients with speciﬁed increases in weekly CSBM frequency and SBM frequency at week 12 (pooled IBS-C phase 3 ITT
population). At week 12, a greater percentage of patients treated with linaclotide met incremental levels of increase in weekly CSBM frequency and
SBM frequency compared with placebo patients (p < 0.0001 for linaclotide compared with placebo for each level of improvement using Fisher’s exact
test for both CSBM and SBM frequency).
© 2013 Ironwood Pharmaceuticals.
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symptoms of abdominal pain and CSBMs, the compo-
nents of the FDA endpoint. In addition, we evaluated
the linaclotide-treated FDA non-responders for symp-
tom improvement in SBMs, IBS global endpoints, and
treatment satisfaction. For each of these six endpoints,
the linaclotide-treated FDA non-responders had a
higher rate of improvement than the placebo patients
in the ITT Population with non-overlapping 95% CIs
(see Figs 1 and 2). For example, when considering SBM
frequency, 62% of linaclotide-treated FDA non-
responders reported improvement, compared with
46% of ITT placebo patients. This result is consistent
with SBM frequency results in the overall ITT popu-
lation, which showed that a greater percentage of
linaclotide-treated patients met SBM frequency
improvement thresholds when compared with pla-
cebo-treated patients (Fig. 4). These results indicate
that linaclotide-treated patients who were classiﬁed as
FDA non-responders are experiencing improvement in
their IBS symptoms above what is seen in the placebo
group.
These ﬁndings illustrate the limitations of using a
dichotomous endpoint to simply classify an IBS-C
patient as a ‘Responder’ or ‘Non-responder’. The
majority of linaclotide-treated patients who were clas-
siﬁed as non-responders using the FDA Responder
Endpoint reported the degree of improvement in their
abdominal pain and/or stool frequency as at least
‘somewhat relieved’ at week 12. These results high-
light the difference between a patient responding to
treatment and a patient being classiﬁed as a responder.
Thus, while the FDA Responder Endpoint for IBS trials
appears to accurately distinguish an efﬁcacious thera-
peutic agent from placebo, the use of a dichotomous
responder endpoint may not accurately convey the
scope of clinical improvements on the hallmark
symptoms of IBS-C (abdominal pain and BM infre-
quency). While responder endpoints may be useful for
assessing if a treatment warrants FDA marketing
approval, they provide limited information for the
clinician to make treatment decisions speciﬁc to the
individual patient’s IBS-C symptoms and may signif-
icantly underestimate a patient’s true clinical
response.
There are some important limitations to these
analyses. First, the use of PRCQs, which require
patients to rate their symptoms in relation to their
status at baseline, are susceptible to potential recall
bias. However, improvement trends similar to those
observed for the PRCQs were seen for adequate relief
and treatment satisfaction (parameters that are not
measured relative to baseline). Second, this post-hoc
analysis was conducted in patients meeting Rome II
criteria for IBS-C, and may not sufﬁciently represent
patients with less-severe symptoms. Lastly, it should
be noted that the number of male patients in these
trials (composing only 5–11% of the analysis subpop-
ulations) is lower than IBS incidence rates in males
observed in epidemiologic studies.
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